Cambridge, MA-based Foundation Medicine, the developer of genomic-based cancer diagnostics, said today it has named Michael Pellini as its new CEO. Pellini was previously the president of Clarient, a unit of GE Healthcare. He replaces Alexis Borisy, a partner at Third Rock Ventures who was Foundation’s original CEO. Borisy will remain on Foundation Medicine’s board as chairman.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
